Information about warrants of series TO 6 B

In connection with the Company's rights issue of units which was resolved by the extraordinary general meeting on June 8, 2023, 234,582,810 warrants of series TO 6 B were issued. Each warrant of series TO 6 B entitles the holder to subscribe for one (1) new B-share in CLS at a price of SEK 0.10 per share during the exercise period that runs from January 23, 2024, until and including February 6, 2024.

At full subscription of warrants of series TO 6 B, the Company will be provided proceeds of approximately SEK 23.5 million before deduction of transaction related costs of maximum approximately SEK 1.5 million. Proceeds received from the warrant exercise are intended to supplement the issue proceeds received in connection with the Company's rights issue of units. The proceeds are thus intended for continued sales, commercial launch and market establishment as well as for ongoing clinical development and new clinical collaborations to support market approval, reimbursement and commercialization.

Upon full exercise of warrants of series TO 6 B, the number of shares in CLS will increase by 234,582,810 B-shares to a total of 1,570,341,299 shares (of which 600,000 A-shares) and the share capital will increase by approximately SEK 2,708,939.05 to approximately SEK 18,134,145.72. The dilution at full subscription amounts to approximately 14.94 percent of the capital and 14.89 percent of the votes.

An information brochure containing summary information about the Company and the offer (in Swedish and English) are available on the websites of CLS, Sedermera Corporate Finance AB's, Redeye AB's and Nordic Issuing AB's respective websites (www.clinicallaser.se, www.sedermera.se, www.redeye.se, www.nordic-issuing.se). Complete terms and conditions for warrants of series TO 6 B are available on the Company's website.

How to exercise warrants of series TO 6 B

For warrants not to expire worthless, warrant holders must subscribe for new B-shares, with the support of warrants, at 17:00 CET on February 6, 2024, at the latest, alternatively sell warrants no later than the February 2, 2024.

Warrants can be registered in two ways:

1. In a securities custody account with a bank or other nominee (for example, Avanza or Nordnet), in an investment savings account (Sw. Investeringssparkonto) or endowment account (Sw. Kapitalförsäkring). The warrants are then nominee registered.

2. In a VP-account (a VP-account starts with three zeros). The warrants are then directly registered.

If warrants are nominee registered

Subscription and payment of new B-shares, with the support of warrants, shall be made to the account-holding bank/nominee with which the warrants are registered. The subscription and payment shall be made in accordance with the instructions from each such bank or nominee. Usually, the bank/nominee sends out a digital notice to the account holder, otherwise it is usually enough to log into the securities custody account from the first day in the exercise period in order to get instructions on how to exercise warrants for subscription of new shares. The warrant holder is advised to contact its bank or trustee in the event that these instructions are not found. Please note that banks and other nominees may set different time limits for subscription, hence it is recommended to contact the account-holding bank/nominee early in the exercise period to obtain information about subscription and payment. An information brochure will be sent out to most nominee registered warrant holders. Subscribed and paid for B-shares may be registered as "interim shares" or "IA" into your securities custody account until registration of the issue is completed with the Swedish Companies Registration Office, whereby interim shares will automatically be converted to ordinary B-shares in CLS.

If your warrants are directly registered

No VP-account statement will be sent out. Subscription of new B-shares, with the support of warrants, shall be made by sending a completed subscription form digitally to Nordic Issuing AB. In conjunction with sending the completed subscription form to Nordic Issuing AB, payment must be made in accordance with the payment details stated on the subscription form. Subscription form will be available on Nordic Issuing AB's website (www.nordic-issuing.se).

Completed subscription form and payment must be registered with Nordic Issuing AB no later than 17:00 CET on February 6, 2024. Subscribed and paid for B-shares will be registered as "interim shares" or "IA" into your VP-account until registration of the issue is completed with the Swedish Companies Registration Office, whereby interim shares will automatically be converted to ordinary B-shares in CLS.

Investor meetings

Fill or Kill podcast, January 23, 2024. CEO Dan J Mogren participates in an interview on the Fill or Kill podcast. The episode is published via established Swedish podcast applications and web services, such as Spotify.

Redeye theme: Fight Cancer, January 24, 2024. CEO Dan J Mogren participates in the theme event "Fight Cancer". The event is held and made available in Redeye AB's channels.

Video interview, February 1, 2024. CEO Dan J Mogren participates in a video interview at Biostock. The interview is published and made available in Biostock's channels.

Advisors

In connection with the exercise of warrants of series TO 6 B, Sedermera Corporate Finance AB and Redeye AB are Joint Lead Managers. Markets & Corporate Law Nordic AB is legal advisor and Nordic Issuing AB acts as issuing agent.

For more information about the warrants of series TO 6 B, please contact:

Sedermera Corporate Finance AB

Phone: +46 40 615 14 10

E-mail: info@sedermera.se

Website: www.sedermera.se

Redeye AB

Phone: +46 (0)8 545 013 30

E-mail: info@redeye.se

Website: www.redeye.se

For more information about CLS, please contact:

Dan J Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com

Website: www.clinicallaser.se

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.

For more information about CLS, please visit the Company's website: clinicallaser.se (http://file:///C:\Users\anna.spangs\Workplace\Paues%20Åberg\Kunder\Clinial%20Laserthermia%20Systems\clinicallaser.se)